Oxford BioDynamics PLC - Oxford, England-based biotechnology company has two blood testing products on market, the PSE prostate cancer screening test and the CiRT checkpoint inhibitor response test - Raises GBP350,000 via retail share offer at 0.5 pence per share. This is in addition to GBP7.0 million raised by placing and subscription at the same price, announced on Wednesday. Read More
Oxford BioDynamics PLC - Oxford, England-based biotechnology company has two blood testing products on market, the PSE prostate cancer screening test and the CiRT checkpoint inhibitor response test - Plans to raise GBP6 million via placing at a minimum price of 0.5 pence per share, a subscription and GBP500,000 cornerstone investment by OAK Securities. Further, seeks to raise GBP500,000 via retail offer. The placing will be conducted through an accelerated bookbuilding process. Proceeds will be used as working capital to support the continued commercial development of the EpiSwitch product line through partnerships and collaborations with diagnostic and pharmaceutical companies and direct sales as appropriate. Read More
(Alliance News) - London's FTSE 100 closed higher on Monday, although bookmakers suffered, as the UK prime minister played down rumours of a capital gains tax hike and urged investors to back his plans for growth. Read More
(Alliance News) - Oxford BioDynamics PLC on Monday launched a strategic review after warning it would need additional cash resources by early 2025. Read More
(Alliance News) - Oxford BioDynamics PLC on Tuesday reported strong revenue growth on the back of the increased commercialisation of its EpiSwitch genomics platform. Read More
(Alliance News) - Oxford BioDynamics PLC on Tuesday announced the development of a canine cancer diagnostic test based on its EpiSwitch non-invasive platform. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
(Alliance News) - Oxford BioDynamics PLC on Tuesday announced a new partnership with The London Clinic. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
(Alliance News) - Oxford BioDynamics PLC said on Wednesday that it has opened a clinical testing laboratory in the UK to perform EpiSwitch prostate screening tests. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News: Read More
(Correcting headline to show loss widened, revenue rose) Read More
(Correcting headline to show profit and revenue rose) Read More
(Alliance News) - Oxford BioDynamics PLC on Wednesday said its full-year loss narrowed, but saw its revenue jump on contracts for EpiSwitch. Read More
(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday. Read More
Oxford BioDynamics PLC - biotechnology company developing precision medicine tests based on the EpiSwitch 3D genomics platform - Reports that Vulpes Testudo Fund, controlled by Non-Executive Director Stephen Diggle has sold 777,000 shares of one pence each at an average price of 38.3p each. Diggle is now interested in 27.6 million shares in total, through the Vulpes Testudo and Vulpes Life Sciences Funds. These represent approximately 13.62% of Oxford BioDynamics's current issued share capital. Company's market capitalisation is GBP69.79 million. Read More
(Alliance News) - Oxford BioDynamics PLC shares surged on Wednesday as it announced a strategic deal with Bupa UK Insurance to enhance access to a "first-of-its-kind" blood test for cancer patients. Read More
(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday. Read More